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 Background Sipuleucel-T is a US Food and Drug Administration–approved immunotherapy for asymptomatic or minimally 
symptomatic metastatic castration-resistant prostate cancer (mCRPC). Its mechanism of action is not fully under-
stood. This prospective trial evaluated the direct immune effects of systemically administered sipuleucel-T on 
prostatic cancer tissue in the preoperative setting.
 Methods Patients with untreated localized prostate cancer were treated on an open-label Phase II study of sipuleucel-T 
prior to planned radical prostatectomy (RP). Immune infiltrates in RP specimens (posttreatment) and in paired 
pretreatment biopsies were evaluated by immunohistochemistry (IHC). Correlations between circulating immune 
response and IHC were assessed using Spearman rank order.
 Results Of the 42 enrolled patients, 37 were evaluable. Adverse events were primarily transient, mild-to-moderate and infu-
sion related. Patients developed T cell proliferation and interferon-γ responses detectable in the blood following 
treatment. Furthermore, a greater-than-three-fold increase in infiltrating CD3+, CD4+ FOXP3-, and CD8+ T cells was 
observed in the RP tissues compared with the pretreatment biopsy (binomial proportions: all P < .001). This level of T 
cell infiltration was observed at the tumor interface, and was not seen in a control group consisting of 12 concurrent 
patients who did not receive any neoadjuvant treatment prior to RP. The majority of infiltrating T cells were PD-1+ 
and Ki-67+, consistent with activated T cells. Importantly, the magnitude of the circulating immune response did not 
directly correlate with T cell infiltration within the prostate based upon Spearman’s rank order correlation.
 Conclusions This study is the first to demonstrate a local immune effect from the administration of sipuleucel-T. Neoadjuvant 
sipuleucel-T elicits both a systemic antigen-specific T cell response and the recruitment of activated effector T cells 
into the prostate tumor microenvironment.
  JNCI J Natl Cancer Inst (2014) 106(11): dju268 doi:10.1093/jnci/dju268
introduction
Sipuleucel-T is an immunotherapy that improves overall survival 
(OS) in metastatic castration-resistant prostate cancer (mCRPC) 
(1,2). Sipuleucel-T is generated from autologous peripheral 
blood mononuclear cells (PBMC) that are cultured ex vivo with 
recombinant fusion protein (PA2024) composed of prostatic acid 
phosphatase (PAP) and granulocyte-monocyte colony stimulat-
ing factor (GM-CSF). While sipuleucel-T can generate systemic 
immune responses to PA2024 and PAP (3), the direct effect of 
this treatment on the tumor microenvironment is unknown.
To better understand the mechanism of action of sipuleucel-T, a 
multicenter phase 2 neoadjuvant trial administering sipuleucel-T to 
patients with localized prostate cancer, prior to their planned radi-
cal prostatectomy (RP), was undertaken (NeoACT, ClinicalTrials.
gov identifier: NCT00715104). Immune infiltrates in RP specimens 
(posttreatment) as assessed by immunohistochemistry (IHC) were 
compared with those from paired pretreatment biopsies. Immune 
infiltrates were also assessed in prostate biopsy and RP specimens from 
control patients who did not receive any neoadjuvant treatment. We 
show that sipuleucel-T not only induces circulating T cell immune 
responses, but also T cell infiltration in the tumor microenvironment.
Methods
Study Design
This was a single-arm, multicenter phase II trial of neoadjuvant 
sipuleucel-T treatment in men with localized prostate cancer 
administered prior to planned RP. Eligible patients had a normal 
complete blood count, adequate hepatic and renal function, tissue 
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available from a pretreatment prostate biopsy, and were negative 
for HIV, HTLV-1 and -2, and hepatitis B and C. All subjects gave 
written informed consent to participate in the protocol approved 
by the Institutional Review Boards (IRBs) of each participating 
institution. Subjects received sipuleucel-T at the standard two-
week intervals for three planned doses prior to RP (Supplementary 
Figure 1, available online). Sipuleucel-T was started six to seven 
weeks prior to RP, allowing for a two- to three-week interval 
between the final infusion of sipuleucel-T and the RP. Following 
RP, patients were randomized to either receive or not receive a sin-
gle booster of sipuleucel-T treatment at 12 weeks. This manuscript 
details the histologic results of neoadjuvant therapy with sipuleu-
cel-T, the primary objective of this study, as well as the peripheral 
immune responses to sipuleucel-T observed in this clinical setting.
Control group: Prior to this study, the effect of systemically 
administered sipuleucel-T on localized prostate cancer deposits was 
unknown. Consequently, it was felt that randomization to a no-treat-
ment arm was premature and would represent a major accrual chal-
lenge until any treatment effect was better characterized. However, it 
was felt to be critically important to have a negative control available, 
in order to provide confidence that changes observed in the pros-
tates of treated patients represented a true treatment effect. A group 
of patients who underwent RP at the University of California San 
Francisco (UCSF) during the same time period, but who had not 
received any preoperative therapy, served as a reference group and 
were used as negative controls. These control patients were selected 
prior to undergoing any tissue analysis, based on a distribution of 
preoperative Cancer of the Prostate Risk Assessment (CAPRA) risk 
criteria (4), to provide an analogous mix of disease risk to the patients 
participating in the trial (five patients with CAPRA scores 0–2, four 
patients with CAPRA scores 3–5, and three patients with CAPRA 
scores 6–10). These patients were selected from the broader surgi-
cal population that routinely provides written consent for the use 
of their specimens for research (UCSF IRB approved protocol for 
human subjects research #11-05226).
Study Endpoints
The primary outcome measure was the change in the number of 
infiltrating CD3+ T cells/μm2 within the prostate tissue between 
the paired biopsy and RP specimens, as quantified by immunohisto-
chemistry (IHC) and image analysis. Secondary endpoints included: 
1) the difference in the number of infiltrating T cell subsets (cytotoxic 
CD8+, helper CD4+ FOXP3-, and regulatory CD4+ FOXP3+ T cells) 
between the biopsy and the RP, as quantified by IHC and image anal-
ysis, 2) changes from baseline to posttreatment of antigen-specific T 
cell responses in peripheral blood as measured by T cell proliferation 
and enzyme-linked immunospot (ELISPOT) assays, and 3) safety.
Systemic Immune Response Assays
T cell proliferation and ELISPOT assays were performed as pre-
viously described (Supplementary Methods, available online) (5).
Immunohistochemistry
Immunohistochemistry was performed using standard methods 
(Supplementary Methods, available online). Stained slides were 
then scanned with an automated microscope scanner (Aperio 
Scanscope XT, Aperio, Buffalo Grove, IL). For RP sections, tissue 
was designated into three distinct compartments: benign glands, 
tumor centers, and tumor interfaces. Five randomly selected fields 
(0.25 mm2, original magnification 20×, 0.5 µm per pixel resolution) 
from each compartment were then captured from each slide with 
ImageScope software (Aperio). Tumor interfaces were defined as 
fields where malignant and benign glands were present. Automatic 
cell counts for single- and double-stained cells were determined 
for each field with color-specific algorithms in Axiovision software 
(Zeiss, Peabody, MA). The cell count for each compartment is 
reported as the mean for each of the five quantitated fields.
Statistical Analysis
This study was designed to detect activity within prostate tissue as 
measured by a change in the CD3+ T cell count/μm2 between the 
pretreatment biopsy and the RP tissue following sipuleucel-T infu-
sions. Accrual of 30 patients was required to recognize a two-fold 
increase from baseline in at least 40% of the patient cohort, com-
pared with only 15%. This assumed a power of 90% and a directional 
5% statistical significance level based upon an exact binomial test.
One-way analysis of variance methods for repeated measures 
were used to test for overall differences in mean IHC results among 
the biopsy sample and three RP tissue compartments (Statistica v6.0, 
Statview, Cary, NC). Newman-Keuls post-hoc tests were performed 
to identify pairwise differences among the tissue types if there was 
an overall statistical difference (probability value < 0.05). Because 
patients were not randomized to treatment with sipuleucel-T, the 
treated and untreated cohorts were analyzed separately. Complete 
data were available for these analyses. For the analysis of the prolif-
eration and ELISPOT assays, nonparametric methods were applied 
because of the frequency of zero measurements. For each immune 
response, the Wilcoxon matched pairs test was performed to com-
pare the baseline distribution with each follow-up time point (pre-
RP, weeks six and 12 post-RP). The Spearman rank order correlation 
was used and analyzed with a t test to evaluate the relationships 
between blood immune outcomes and between peripheral blood 
outcomes and tissue T cell components from the IHC analysis. No 
adjustment was made for multiple comparisons for these explora-
tory analyses. All statistical tests were two-sided, except for a test of 
a binomial proportion to compare the proportion of patients achiev-
ing a two- or three-fold increase in the RP specimen vs the pretreat-
ment biopsy with a null hypothesis of 15% of the patients.
results
Patients and Treatment
Between September 29, 2008 and June 6, 2011, a total of 42 
patients were enrolled from five sites. Nineteen (45.2%) patients 
had low-risk disease, 14 (33.3%) had intermediate-risk disease, 
and nine (21.4%) had high-risk disease as defined by the CAPRA 
score prior to RP (Table 1). One patient withdrew consent prior to 
receiving any therapy, and was therefore excluded from the patients 
evaluated for immune responses (Supplementary Figure 2, avail-
able online). Of the 41 patients, 38 received all three pre-RP infu-
sions of sipuleucel-T. Three patients received two infusions, but 
were unable to receive a third due to insufficient blood flow for 
leukapheresis (n = 1), error at the apheresis center (n = 1), and a 
patient failing to arrive for a treatment appointment (n = 1). Of the 
Vol. 106, Issue 11  |  dju268  |  November 12, 20143 of 9 Article | JNCI
41 patients who received sipuleucel-T, 37 underwent RP and were 
evaluable, three withdrew consent, and one was lost to follow up. 
Laparoscopic prostatectomy was performed in 29 patients, and ret-
ropubic RP was performed in eight patients. The 41 patients who 
received at least one leukapheresis procedure were considered in 
the assessment of safety. The 37 patients who underwent RP were 
evaluable for peripheral immune responses and immune infiltrates.
Safety
Adverse events (AEs) prior to RP were reported in a total of 34/42 
patients (81.0%), and most were Grade 1–2 and transient (Table 2) 
and consistent with other trials (2). Two serious AEs (SAEs) were 
reported prior to RP (B cell lymphoma [1/41] and infusion-related 
reaction [1/41]). The most frequent AEs (>10% of patients) that 
occurred within one day after infusion were Grade 1–2 fatigue, 
headache, and myalgia. There were only two treatment-related 
Grade 3 AEs that occurred prior to RP: arthralgia (1/41, 2.4%) 
and flu-like reaction (1/41, 2.4%). Sipuleucel-T did not appear 
to affect operative complications, procedure time, or estimated 
blood loss.
Clinical Efficacy
Downstaging was not observed at the time of RP relative to base-
line. Six patients (16%) had downgrading of their Gleason Scores 
at RP relative to pretreatment biopsies, while eight had upgrading 
(22%). In the control group, one patient (8%) had downgrading of 
Gleason Score at RP relative to pretreatment biopsies, while two 
had upgrading (17%).
Systemic Immune Response
T cell proliferative responses to PA2024 were induced by treat-
ment and persisted through week 12 post-RP (Figure 1A). T cell 
proliferation to PAP was also seen in some patients, though less 
frequently (Figure 1B). IFN-γ responses to PA2024, and to a lesser 
degree PAP, were also induced by treatment pre-RP (Figure 1, C 
and D).
Immune Response in Prostate Tissues
The frequencies of immune cells in the RP tissue were quanti-
tated in three compartments: benign glands, tumor interface, and 
tumor center (Figure 2A). T cells were evident in the RP tissues of 
sipuleucel-T–treated patients and were concentrated primarily at 
the tumor interface (Figure 2B). Increased infiltration of CD3+ T 
cells was evident at the tumor interface (mean = 6.39 x 10–3/μm2, 
95% confidence interval [CI]  =  5.20 to 7.58 x 10–3/μm2) com-
pared with the pretreatment biopsy (mean = 2.33 x 10–3/μm2, 95% 
CI = 1.66 to 2.99 x 10–3/μm2, P < .001) (Figure 2C). A greater-
than-three-fold increase was seen in 57% (95% CI  =  39% to 
79%) of the patients treated with sipuleucel-T. This was sta-
tistically significantly higher than the null hypothesis of only a 
two-fold increase of 15% (P < .001). This increased infiltration 
Table 1. Baseline demographics and disease characteristics
Characteristic Patients, No. (%)
Patients enrolled 42 (100.0)
Age, y
 Median 61
 Range 51–72
Weight, lbs
 Median 187
 Range 147–309
Race
 Caucasian 41 (97.6)
 Asian 1 (2.4)
ECOG PS = 0 42 (100.0)
Gleason sum at baseline
 ≤6 10 (23.8)
 7 18 (42.9)
 ≥8 14 (33.3)
Clinical stage
 T1B 1 (2.4)
 T1C 21 (50.0)
 T2A 7 (16.7)
 T2B 2 (4.8)
 T2C 10 (23.8)
 T3A 1 (2.4)
Nodal status
 N0 16 (38.1)
 NX 26 (61.9)
Distant metastasis
 M0 17 (40.5)
 MX 25 (59.5)
PSA, ng/mL
 Median 6
 Range 1–92
LDH (range), U/L
 Median 156
 Range 114–567
Hemoglobin (range), g/dL
 Median 15
 Range 13–17
Alk phos (range), U/L
 Median 64
 Range 34–154
CAPRA Score
 0–2 19 (45.2)
 3–5 14 (33.3)
 6–10 9 (21.4)
* CAPRA = Cancer of the Prostate Risk Assessment; ECOG = Eastern 
Cooperative Oncology Group; LDH = lactic dehdrogenase; PSA = prostate-
specific antigen.
Table 2. Adverse events*
Adverse events Total, No. (%)
Fatigue 18 (42.9)
Paraesthesia oral 10 (23.8)
Headache 8 (19.0)
Citrate toxicity 7 (16.7)
Chills 5 (11.9)
Myalgia 5 (11.9)
Nausea 5 (11.9)
Contusion 4 (9.5)
Diarrhea 4 (9.5)
Muscle spasms 4 (9.5)
Anxiety 3 (7.1)
Arthralgia 3 (7.1)
Paraesthesia 3 (7.1)
* Adverse events (AEs) that occurred from the first leukapheresis through prior 
to radical prostatectomy in less than 5% of patients are shown. Three grade 
3–4 AEs (arthralgia, Infusion reaction, and B-cell lymphoma) were reported. 
There were no grade 5 AEs.
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by CD3+ T cells at the tumor interface (mean = 0.95 x 10–3/μm2) 
was not evident in the control group, who did not receive the 
neoadjuvant therapy.
Effector CD4+ FOXP3- helper T cell numbers were increased 
at the tumor interface (mean = 3.95 x 10–3/μm2, 95% CI = 2.98 
to 4.92 x 10–3/μm2) with treatment compared with the biopsy 
(mean = 0.93 x 10–3/μm2, 95% CI = 0.47 to 1.38 x 10–3/μm2, P < .001) 
(Figure 3A). CD8+ cytotoxic T cell numbers were also increased 
at the tumor interface (mean = 2.87 x 10–3/μm2, 95% CI = 2.39 
to 3.36 x 10–3/μm2) compared with the biopsy (mean = 0.65 x 10–
3/μm2, 95% CI = 0.50 to 0.80 x 10–3/μm2, P < .001). CD4+/FOXP3+ 
regulatory T cell (Tregs) numbers were also increased at the tumor 
interface. The majority of T cells at the interface were CD4+ 
helper T cells, with Tregs constituting only a small proportion of 
the T cells (Figure  3B, left panel). Nevertheless, the mean val-
ues among the four tissue compartments for CD3+ T cells, CD8+ 
T cells, CD4+ FoxP3- effector T cells, and CD4+/FOXP3+ Tregs 
were each statistically significantly different overall (all P < .0001, 
analysis of variance) with sipuleucel-T treatment (Figure 3B, left 
panel). Natural killer cell numbers were not increased in the RP 
specimens following sipuleucel-T treatment, indicating that the 
lymphocyte infiltration induced by sipuleucel-T was not because 
of nonspecific recruitment of immune cells to the prostate. Nearly 
half of CD3 T lymphocytes at the tumor interface of treated 
patients expressed PD-1 (Figure  4, A and B). Because PD-1 is 
expressed on both activated and exhausted T cells, we performed 
staining for Ki-67 as a marker of activated, proliferating T cells. 
In patients treated with sipuleucel-T, we found that the majority 
of CD3 T cells in interface and tumor centers were also Ki-67+ 
(Figure  4C). While T cells could rarely be found as clusters as 
seen with tertiary lymphoid structures (6), the increase of T cells 
was predominantly because of diffuse infiltration at the interface 
(Supplementary Figure  3A, available online). B cells were also 
increased at the tumor interface (Supplementary Figure 3B, avail-
able online). These lymphocytes were not consistently clustered 
at high endothelial venules (HEV), nor was there a difference in 
the density of HEV to account for the changes seen in the treated 
patients (Supplementary Figure 3, C and D, available online).
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Figure 1. Antigen-specific circulating T cell responses following sipuleu-
cel-T treatment. T cell proliferation to PA2024 (A) and PAP (B) were meas-
ured by 3H-thymidine incorporation in cultured PBMC. IFNγ responses 
to PA2024 (C) and prostatic acid phosphatase (D) were measured by 
enzyme-linked immunospot (ELISPOT) in cultured peripheral blood 
mononuclear cells. Each measure is shown at baseline, pre–radical 
prostatectomy (RP) (following sipuleucel-T infusions), six weeks post-
RP, and 12 weeks post-RP. Horizontal bars represent the median values 
of patients with all four timepoints available. * Denotes two-sided P 
under .05, Wilcoxon matched pairs test for comparison with baseline. 
PA2024 = recombinant fusion protein; PAP = prostatic acid phosphatase; 
RP = radical prostatectomy.
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We examined whether there were any relationships between 
systemic immune responses and the magnitude of T cell infiltra-
tion in the tumors. We found no correlation between the pre-RP 
immune responses (proliferation or ELISPOT response to either 
PA2024 or PAP) and the CD3+, CD4+FOXP3-, and CD8+ T cell 
infiltration in any of the RP compartments (Spearman rank order 
correlations: P > .07 for all, data not shown). When the changes in 
immune responses from baseline to pre-RP were analyzed, how-
ever, there were statistically significant correlations between PAP 
IFNγ ELISPOT responses and CD3 infiltration in benign and 
tumor tissue (Spearman rank order correlations: t test P = .01 for 
each) (Table 3). There was also a statistically significant correlation 
between the change in PA2024 IFNγ ELISPOT and CD4 T cell 
infiltration at the interface (Table 3).
Discussion
Immunotherapy with sipuleucel-T is approved by the FDA for 
treatment of asymptomatic or minimally symptomatic metastatic 
CRPC. While the proposed mechanism of action of sipuleucel-T 
involves the induction of a T cell immune response targeting pros-
tate cancer cells, the effects of sipuleucel-T at a tissue level have not 
been examined prior to this. This study demonstrates that neoad-
juvant sipuleucel-T elicits both a systemic antigen-specific T cell 
response and results in the recruitment of activated effector T cells 
into the prostate tumor microenvironment.
These results demonstrate that neoadjuvant sipuleucel-T 
increases the frequency of CD3+ T cells within the prostate, par-
ticularly at the interface between benign and malignant glands. 
Quantitation of immune cells prior to treatment relied on stains 
from needle biopsies, which may be subject to sampling bias. 
Nevertheless, the recruitment of activated lymphocytes was 
not seen in the control cohort, which did not receive neoad-
juvant therapy. It is not known if this recruitment of T cells 
also occurs in metastatic deposits of mCRPC patients treated 
with sipuleucel-T, or if this can account for the OS benefit 
that has been observed with sipuleucel-T in phase 3 mCRPC 
trials. However, infiltration of tumor tissues by T cells can be 
associated with improved clinical outcomes in many different 
malignancies (7,8). Specifically, recruitment of Th1 immune 
A
TC
TI
BE
UntreatedSipuleucel-T
C
   
C
D
3+ /#(
C
el
ls
/a
re
a
µm
2 )
Biopsy Benign Interface Center
RP
Biopsy Benign Interface Center
RP
**
*
Sipuleucel-T Untreated
3
D
C
8
D
C
4
D
C
3
P
X
O
F
65
D
C
B
0.005
0.010
0.015
0.020
0.025
0.005
0.010
0.015
0.020
0.025
Figure 2. Frequency of intraprostatic T cells in biopsy and radical pros-
tatectomy (RP) sections from patients treated with sipuleucel-T and 
untreated patients. A) Representative RP section with benign glands, 
tumor interface, and tumor center are depicted. B) Representative digi-
tal micrographs of immunohistochemistry-stained RP sections from 
patients treated with sipuleucel-T (left panels) and untreated patients 
(right panels) showing the tumor interface between benign and tumor 
tissue. Sections are stained for CD3 (red) /CD8 (brown) in the top pan-
els, CD4 (red)/FOXP3 (brown) in the middle panels, and CD56 (brown) 
in the bottom panels. C) CD3+ T cells were quantitated by digital image 
analysis in prostate biopsies and in the RP sections. Cell frequencies in 
the RP sections were quantified in three compartments: benign glands, 
tumor interface, and tumor center. Means ± 95% confidence interval are 
shown with horizontal lines. * Denotes P under .05, analysis of variance 
(ANOVA) methods for repeated measures with post-hoc comparisons 
with the RP interface compartment. All ANOVA tests were two-sided. 
Scale bars = 100 μm. BE = benign glands; RP = radical prostatectomy; 
TC = tumor center; TI = tumor interface.
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responses and effector/memory T cells represent favorable 
prognostic factors in the “immunoscore” that is being developed 
as a prognostic indicator for multiple malignancies (9,10). These 
findings are consistent with other immunotherapies, including 
anti-CTLA-4 and anti-PD-1 antibodies, that can also lead to 
enhanced recruitment of T cells to the tumor site (11,12). In 
UntreatedSipuleucel-T
8
D
C
+ / #(
C
el
ls
/a
re
a
µm
2 )
C
D
4+
F
O
X
P
3-
/ #(
C
el
ls
/a
re
a
µm
2 )
C
D
4+
F
O
X
P
3+
/ #(
C
el
ls
/a
re
a
µm
2 )
Biopsy Benign Interface Center
RP
Biopsy Benign Interface Center
RP
Biopsy Benign Interface Center
RP
Biopsy Benign Interface Center
RP
Biopsy Benign Interface Center
RP
Biopsy Benign Interface Center
RP
C
D
56
+ /#(
C
el
ls
/a
re
a
µm
2 )
Biopsy Benign Interface Center
RP
Biopsy Benign Interface Center
RP
**
*
**
*
**
*
Sipuleucel-T Untreated
Benign Interface Center
RP
Benign Interface Center
RP
/#(
C
el
ls
/a
re
a
µm
2 )
CD4+FOXP3+
CD4+FOXP3-
CD8+
A
B
0.002
0.004
0.006
0.008
0.002
0.004
0.006
0.008
0.005
0.010
0.015
0.005
0.010
0.015
0.005
0.010
0.015
0.005
0.010
0.015
0.020
0.025
0.005
0.010
0.015
0.005
0.010
0.015
0.005
0.010
0.015
0.005
0.010
0.015
0.020
0.025
Figure 3. Frequency of intraprostatic T cell subsets in biopsy and radi-
cal prostatectomy (RP) sections from patients treated with sipuleucel-T 
and untreated patients. A) Quantitation of CD8+cytotoxic T cells, effector 
CD4+ FOXP3- T cells, regulatory CD4+ FOXP3+ T cells, and CD56+ natural 
killer cells was performed using digital image analysis. Cell frequencies 
in the RP sections were again quantified in three compartments: benign 
glands, tumor interface, and tumor center. B) The relative composition 
of the mean T subset frequencies within the RP is presented. Means ± 
95% confidence intervals are shown with horizontal bars. * Denotes P 
under .05, analysis of variance (ANOVA) methods for repeated meas-
ures with post-hoc comparisons with the RP interface compartment. All 
ANOVA tests were two-sided. RP = radical prostatectomy.
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this trial, digital microscopy was used in image analysis to enu-
merate the frequency of immune cells per unit area, rather than 
relying on more subjective grading (eg, 1+ to 4+). This approach 
allowed both the enumeration of immune cells within the pros-
tate and the definition of the spatial compartments where these 
cells reside.
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Figure  4. Expression of programmed death 1(PD1) and Ki-67 on CD3+ 
T lymphocytes in biopsy and radical prostatectomy (RP) sections 
from patients treated with sipuleucel-T and untreated patients. A) 
Representative digital micrographs of immunohistochemistry-stained RP 
sections from sipuleucel-T–treated and –untreated control patients show-
ing expression of PD1 and Ki-67 on CD3+ T lymphocytes at the tumor inter-
face. Scale bars = 100 μm. B) Quantitation of PD1 and Ki-67 expression on 
CD3+ was performed using digital image analysis on the different tissue 
compartments. Means ± 95% confidence interval are shown with hori-
zontal lines. The relative composition of the mean PD1+ (C) and Ki-67+ (D) 
T frequencies within the RP are presented. * P under .05, analysis of vari-
ance (ANOVA) methods for repeated measures with post-hoc compari-
sons with the RP interface compartment. Scale bars = 100 μm. All ANOVA 
tests were two-sided. RP = radical prostatectomy.
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The concentration of immune cells at the tumor interface of 
prostate cancer patients treated with neoadjuvant sipuleucel-T is an 
intriguing observation. In the setting of colorectal cancer, infiltrat-
ing immune cells are typically localized to the tumor centers and 
the invasive margins, the latter of which would be analogous to the 
“tumor interfaces” described in this study (9,10). The concentra-
tion of immune cells at the tumor interface could potentially reflect 
the timing of treatments: The two to three weeks that separated the 
final sipuleucel-T infusion and the RP may have been insufficient 
to allow for migration into the tumor centers. Alternatively, com-
ponents of the microenvironment may also preferentially position 
treatment-induced cells to specific locations within the prostate. 
These results also demonstrate the heterogeneous distribution of 
an immune infiltrate in the prostate. Indeed, the differences seen 
between biopsies and RPs could have been impacted by sampling 
error introduced by the biopsies. Nevertheless, the untreated 
cohort, which would have been subjected to the same sampling 
effect, did not have a similar change in T cell infiltration.
While other observational studies in prostate cancer have dem-
onstrated that the presence of CD8 T cells in the tumor tissue 
may be prognostic of clinical outcome (13), our study shows that 
both CD8 and effector CD4 T cells were recruited to the tumor 
interface, which is a likely treatment effect. These cell types were 
preferentially recruited to prostate relative to Tregs. Our results do 
not, however, distinguish these effector T cells as Th1 or Th2 cells. 
CD8+ T cells present in the prostate have been previously shown 
to be oligoclonal and expressing PD-1, consistent with these cells 
being exhausted T cells (14). Neoadjuvant sipuleucel-T induced a 
statistically significant increase in the frequency of PD-1+ T cells 
at the tumor interface compared with the pretreatment biopsy 
(post-hoc test: P = .0001), but the presence of Ki-67 on the major-
ity of the T cells indicated that they were not exhausted, but were 
proliferating perhaps to activation signals (eg, antigens) within the 
microenvironment.
In this study, correlation was observed between the immune 
responses seen in the RP tissues and peripheral immune responses 
measured at the time of resection by T cell proliferation or 
ELISPOT assays. This lack of correlation could reflect the limited 
number of patients with detectable systemic responses. Alternatively, 
antigen-specific T cells may have homed to the prostate tissues. 
The T cells recruited to the prostate could also be recognizing 
other antigens resulting from a cascading immune response that 
recognizes other antigens, referred to as epitope spreading. In any 
event, this observation raises issues as to the utility of using circu-
lating immune responses from a single time-point measurement 
as a biomarker reflecting complex biological processes at the site 
of tumor deposits. In contrast, when induced changes in the circu-
lating immune response between baseline and the time of surgery 
were considered, there were correlations with the magnitude of T 
cell infiltrates in the prostate, although these correlations were not 
consistent across all measures. These observations suggest that a 
more dynamic marker reflecting change over time in peripheral 
blood analytes might more accurately reflect changes at the level of 
tissue infiltrates. Future studies in larger cohorts assessing immune 
responses to such antigens and to a broader panel of prostate anti-
gens may help further define the relevant circulating markers that 
correlate with responses within the tissue.
Assessing for the expression of immunologic cues that recruit 
immune cells within the tumor microenvironment could poten-
tially help to identify patients who might respond to sipuleucel-T 
and perhaps other immunotherapies. Indeed, gene expression sig-
natures associated with immune and/or clinical responses in other 
diseases that are being developed include different chemokines that 
contribute to T cell localization (15–17).
Because we are administering a treatment prior to planned 
definitive surgery, the time window between sipuleucel-T treat-
ment and RP was narrow, which represents a potential limitation of 
our study. Evolution of the immune cell infiltration over time was 
not captured by our study. The tumor microenvironment in pri-
mary tumors is different from metastasis, so immune cell recruit-
ment could be different in the advanced disease setting.
Nevertheless, these results also provide further rationale for 
combination trials using sipuleucel-T with other treatments that 
can augment T cell immunity, such as ipilimumab and cytokines, 
including IL-7 and IL-15. Moreover, the expression of PD-1 on the 
intraprostatic T cells induced by sipuleucel-T would also argue for 
combining this treatment with PD-1/PD-L1–targeting therapies 
(18). Finally, our results demonstrate how neoadjuvant trials with 
Table 3. Correlations between the change in enzyme-linked immunospot (ELISPOT) response and frequency of T cells in the radical pros-
tatectomy tissue (n = 27)
Compartment
PA2024 ELISPOT change  PAP ELISPOT change
Spearman
P
Spearman
Pcorrelation correlation
CD3 benign 0.16 .44 0.48 .01
CD3 interface 0.23 .24 0.33 .09
CD3 center 0.18 .37 0.49 .01
CD4 benign 0.03 .90 0.02 .92
CD4 interface 0.48 .01 0 .00
CD4 center 0.24 .22 0.12 .55
CD8 benign 0.22 .27 0.22 .28
CD8 interface 0.27 .18 0.13 .52
CD8 center 0.16 .42 0.25 .21
* Spearman rank order correlations were calculated between the change in ELISPOT response and the frequency of the specified T cells in the designated tissue 
compartment. Statistical significance was assessed using a two-sided t test. Change in ELISPOT = pre–radical prostatectomy ELISPOT – baseline ELISPOT. 
ELISPOT = enzyme-linked immunospot; PAP = prostatic acid phosphatase.
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immunotherapies can provide opportunities for evaluating human 
immune responses in situ. Such an approach could be applied to 
other prostate cancer immunotherapies (19–21).
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